コンパニオン診断市場- 世界の産業規模、シェア、動向、機会、予測、製品・サービス別、技術別、疾患適応症別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

コンパニオン診断の世界市場規模は、2024年に61億7,000万米ドルで、予測期間中のCAGRは11.94%で、2030年には121億4,000万米ドルに達すると予測されています。

コンパニオン診断薬は、治療薬と併用される医療機器で、特定の個人に対する薬剤の影響や適合性を評価するために使用されます。これらの診断薬は、治療薬と一緒に開発され、その特徴に基づいて、治療薬に反応する患者群や治療薬に適さない患者群を特定します。ヘルスケア専門家は、患者に対する特定の治療の有効性を評価するためにこの装置を利用します。2020年、ロシュは肺がん治療におけるEGFRチロシンキナーゼ阻害剤の適切な使用の判定を支援するコバスEGFR変異検査v2コンパニオン診断のFDA承認を取得しました。コンパニオン診断（CDx）は、治療薬と共同開発された臨床検査で、治療薬が奏効する患者、奏効しない患者を同定します。CDxによって、対応する薬剤による治療が可能な患者群と不可能な患者群を特定することができます。CDxは、治療薬のベネフィット、副作用、関連リスクを評価し、患者の安全性を確保するのに役立ちます。

コンパニオン診断薬の世界市場は、オーダーメイド治療に対する患者の需要の増加、個別化された薬剤の適用拡大、慢性疾患の有病率の増加、薬剤関連アレルギーの発生率の増加などの要因によって牽引されています。これらの要因は、カスタマイズされたCDxの開発に寄与し、市場の成長を促進します。さらに、CDx検査は、費用対効果、高感度、短時間での迅速かつ正確な結果などの利点を提供し、コンパニオン診断薬市場の成長をさらに促進しています。

主な市場促進要因

NGSベースの技術に対する需要の増加

主な市場課題

コンパニオン診断技術の認識不足と高コスト

主な市場動向

プロモーション活動の重要性の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のコンパニオン診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品・サービス別（キットおよび試薬、アッセイ、ソフトウェア、およびサービス）
  • 技術別（PCR、NGS、in-situハイブリダイゼーション、免疫組織化学など）
  • 疾患適応症別（オンコロジー、神経学、心臓学、感染症など）
  • 用途別（体外診断、創薬、その他）
  • エンドユーザー別（製薬・バイオテクノロジー企業、調査機関、受託研究機関など）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のコンパニオン診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のコンパニオン診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のコンパニオン診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のコンパニオン診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのコンパニオン診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界のコンパニオン診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Abbott Laboratories Inc.
• Agilent Technologies Inc.
• F.Hoffmann-La Roche Ltd
• Biomerieux SA
• Qiagen NV
• Siemens Healthcare
• Thermo Fisher Scientific Inc.
• Danaher Corporation（Beckman Coulter Inc.）
• Myriad Genetics Inc.
• Illumina Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Companion Diagnostic Market was valued at USD 6.17 Billion in 2024 and is expected to reach USD 12.14 Billion by 2030 with a CAGR of 11.94% during the forecast period. Companion diagnostics are medical devices used in conjunction with therapeutic drugs to assess the impact and suitability of drugs for specific individuals. These diagnostics are developed alongside drugs to identify patient groups that respond to or are not suitable for the therapy based on their characteristics. Healthcare professionals utilize this device to evaluate the effectiveness of a particular treatment for a patient. In 2020, Roche obtained FDA approval for the Cobas EGFR Mutation Test v2 companion diagnostic, which assists in determining the appropriate use of EGFR tyrosine kinase inhibitors for lung cancer treatment. Companion Diagnostic (CDx) is a clinical test co-developed with a therapeutic drug to identify patients who will respond or not respond to the drug. It enables the identification of patient groups that can or cannot be treated with the corresponding drug. CDx helps practitioners evaluate the benefits, side effects, and associated risks of therapeutic drugs, ensuring patient safety.

The global Companion Diagnostics Market is driven by factors such as increasing patient demand for tailored therapy, expanded applications of personalized medications, higher prevalence of chronic diseases, and growing incidence of medication-related allergies. These factors contribute to the development of customized CDx, promoting market growth. Additionally, CDx tests offer advantages such as cost-effectiveness, high sensitivity, and rapid and accurate results within shorter time frames, further fueling the growth of the Companion Diagnostics Market.

Key Market Drivers

Increasing Demand for NGS-Based Technology

The growing demand for next-generation sequencing (NGS) technology, with its exceptional capability to identify rare variants, plays a critical role in the continued success and wider distribution of companion diagnostics solutions in the companion diagnostics market. By utilizing NGS panels, a single test has the potential to aid in the treatment of numerous types of cancers, offering a more comprehensive approach to personalized medicine.

For instance, in July 2022, Almac Diagnostic forged a strategic partnership with AstraZeneca, a leading pharmaceutical company, to collaboratively develop and commercialize multiple companion diagnostic (CDx) products. These innovative CDx solutions will be based on cutting-edge NGS (next-generation sequencing) and qPCR-based (quantitative polymerase chain reaction) technologies, further advancing the field of precision medicine and enhancing patient care. Through this collaboration, Almac Diagnostic and AstraZeneca aim to improve the accuracy and effectiveness of diagnostics, enabling targeted therapies and personalized treatment plans for patients. This partnership demonstrates the commitment of both companies to drive innovation in the field of companion diagnostics and contribute to the advancement of precision medicine.

By leveraging the power of NGS and qPCR technologies, Almac Diagnostic and AstraZeneca envision a future where companion diagnostics play a pivotal role in guiding treatment decisions and improving patient outcomes across various therapeutic areas. This collaboration represents a significant step forward in the development of advanced diagnostic solutions that will revolutionize the way diseases are diagnosed and treated. With the combination of cutting-edge technologies and strategic partnerships, the field of precision medicine is poised to make significant strides in improving patient care and transforming healthcare on a global scale.

Key Market Challenges

Lack of Awareness and High Cost of Companion Diagnostics Techniques

While immunotherapy has shown significant promise in the treatment of cancer, its high cost has limited widespread patient access. As a result, physicians may opt to combine treatments, which can extend the duration of treatment from five months to over three years. With longer treatment duration comes a greater financial burden, as the cost of personalized immunotherapies is also substantial. In fact, the cost of cancer immunotherapies can far exceed that of other treatment options such as chemotherapy or radiation therapy. Consequently, the high cost of immuno-oncology treatments is believed to impede the growth of the companion diagnostics market. This financial barrier highlights the need for continued research and innovation to develop more affordable and accessible immunotherapies for cancer patients.

Key Market Trends

Growing Importance of Promotional Activities

The increasing significance of promotional activities represents a key trend in the companion diagnostics market. Companion diagnostics, due to their specificity in being applicable only to particular drugs, are not as extensively marketed as other available test kits and devices in the market. Therefore, it is crucial to give greater attention to improving the distribution network and enhancing the availability of products to end users. In terms of advertising sources, internet channels and search engines are among the most vital, considering their higher visibility and the limited return on investment and visibility of other media.

Furthermore, besides boosting sales, emphasis is placed on product functionality, accuracy, and vendors' after-sales services, while marketing communication takes a back seat. Limited promotion activities pose challenges in reaching the target market and understanding a company's competitive position. To attract customers to a company website, the publication of multiple blogs and newsletters can be beneficial. This approach allows businesses to sustain their marketing campaigns over an extended period and attract repeat visitors. As the market continues to witness product enhancements, vendors are increasingly recognizing the importance of promotional activities, and this trend is expected to gain momentum, thereby supporting the growth of the global companion diagnostics market throughout the forecast period.

Key Market Players

• Abbott Laboratories Inc.
• Agilent Technologies Inc.
• F.Hoffmann-La Roche Ltd
• Biomerieux SA
• Qiagen NV
• Siemens Healthcare
• Thermo Fisher Scientific Inc.
• Danaher Corporation (Beckman Coulter Inc.)
• Myriad Genetics Inc.
• Illumina Inc.

Report Scope:

In this report, the Global Companion Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Companion Diagnostic Market, By Product and Services:

• Kits and Reagents
• Assays
• Software
• Services

Companion Diagnostic Market, By Technology:

• PCR
• NGS
• In-Situ Hybridization
• Immunohistochemistry
• Others

Companion Diagnostic Market, By Disease Indication:

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Others

Companion Diagnostic Market, By Application:

• In-Vitro Diagnostics
• Drug Discovery
• Others

Companion Diagnostic Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Research Laboratories
• Contract Research Organization Others

Companion Diagnostic Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Companion Diagnostic Market.

Available Customizations:

Global Companion Diagnostic market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Companion Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product and Services (Kits and Reagents, Assays, Software, and Services)
  • 5.2.2. By Technology (PCR, NGS, In-Situ Hybridization, Immunohistochemistry, and Others)
  • 5.2.3. By Disease Indication (Oncology, Neurology, Cardiology, Infectious Diseases, and Others)
  • 5.2.4. By Application (In-Vitro Diagnostics, Drug Discovery, and Others)
  • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, Contract Research Organization, and Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Companion Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product and Services
  • 6.2.2. By Technology
  • 6.2.3. By Disease Indication
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Companion Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product and Services
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Disease Indication
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Companion Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product and Services
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Disease Indication
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Companion Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product and Services
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Disease Indication
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Companion Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product and Services
  • 7.2.2. By Technology
  • 7.2.3. By Disease Indication
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Companion Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product and Services
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Disease Indication
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. United Kingdom Companion Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product and Services
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Disease Indication
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. Italy Companion Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product and Services
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Disease Indication
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. France Companion Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product and Services
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Disease Indication
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Companion Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product and Services
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Disease Indication
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia-Pacific Companion Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product and Services
  • 8.2.2. By Technology
  • 8.2.3. By Disease Indication
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Companion Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product and Services
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Disease Indication
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Companion Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product and Services
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Disease Indication
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Companion Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product and Services
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Disease Indication
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Companion Diagnostic Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product and Services
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Disease Indication
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Companion Diagnostic Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product and Services
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Disease Indication
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. South America Companion Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product and Services
  • 9.2.2. By Technology
  • 9.2.3. By Disease Indication
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Companion Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product and Services
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Disease Indication
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Companion Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product and Services
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Disease Indication
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Companion Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product and Services
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Disease Indication
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. Middle East and Africa Companion Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product and Services
  • 10.2.2. By Technology
  • 10.2.3. By Disease Indication
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Companion Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product and Services
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Disease Indication
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Companion Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product and Services
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Disease Indication
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Companion Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product and Services
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Disease Indication
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Companion Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. F.Hoffmann-La Roche Ltd
• 15.4. Biomerieux SA
• 15.5. Qiagen NV
• 15.6. Siemens Healthcare
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. Danaher Corporation (Beckman Coulter Inc.)
• 15.9. Myriad Genetics Inc.
• 15.10. Illumina Inc.

16. Strategic Recommendations

17. About Us & Disclaimer